Reneo Pharmaceuticals Inc. (RPHM) NASDAQ

$6.55 0.21 (3.31%)

Market Cap: $218.19M

As of 12/01/23 04:00 PM EST. Market closed.

(RPHM)

Reneo Pharmaceuticals Inc. (RPHM)
NASDAQ

$6.55
0.21 (3.31%)

Market Cap: $218.19M

As of 12/01/23 04:00 PM EST. Market closed.

Add to Portfolio

reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. many of these diseases are associated with deficits in cellular metabolism and energy production. our goal is to improve daily function and quality of life of patients suffering from these diseases, most specifically, by improving how their mitochondria work, ... read more

reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. many of these diseases are associated with deficits in cellular metabolism and energy production. our goal is to improve daily function and quality of life of patients suffering from these diseases, most specifically, by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness and wasting. we are currently advancing a novel molecule into several diseases. our experienced team of drug development experts, who have collaborated in many successful programs, are dedicated and passionate about finding effective therapies for these complex rare diseases. read less

COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
URL
Address
.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Address
.
PRICE CHART FOR RENEO PHARMACEUTICALS INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$6.29
Previous Close
$6.34
Days Range
$6.32 - $6.75
52 week range
$1.79 - $11.30
Volume
761,629
Avg. Volume (30 days)
218,839
Market Cap
$218.19M
Dividend Yield
-
P/E
-
Shares Outstanding
33,311,787
Open
$6.29
Previous Close
$6.34
Days Range
$6.32 - $6.75
52 week range
$1.79 - $11.30
Volume
761,629
Avg. Volume (30 days)
218,839
Market Cap
$218.19M
Dividend Yield
-
P/E
-
Shares Outstanding
33,311,787
FINANCIAL STATEMENTS FOR RENEO PHARMACEUTICALS INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR RENEO PHARMACEUTICALS INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Hall AshleyChief Development OfficerAug 28, 2023 Option Exercise$1.8015,62528,12555,225Aug 29, 2023, 05:04 PM
Hall AshleyChief Development OfficerAug 28, 2023 Sale$6.2815,62598,05839,600Aug 29, 2023, 05:04 PM
Novo Holdings A/S10% OwnerJun 23, 2023 Sale$7.10100,000709,7403,330,337Jun 23, 2023, 07:15 PM
O'Donnell NiallDirectorMay 08, 2023 Buy$8.00125,0001,000,0002,188,713May 10, 2023, 05:47 PM
Cruse MichaelChief Operating OfficerSep 01, 2022 Buy$3.397,50025,44713,697Sep 02, 2022, 05:12 PM
GREY MICHAEL GExecutive ChairmanAug 31, 2022 Option Exercise$1.9750,00098,50050,000Sep 02, 2022, 05:10 PM
Cruse MichaelChief Operating OfficerAug 29, 2022 Buy$3.241,1403,6941,140Aug 31, 2022, 05:47 PM
Cruse MichaelChief Operating OfficerAug 29, 2022 Buy$3.248326930,783Aug 31, 2022, 05:47 PM
Cruse MichaelChief Operating OfficerAug 31, 2022 Buy$3.213,21210,3076,197Aug 31, 2022, 05:47 PM
Cruse MichaelChief Operating OfficerAug 30, 2022 Buy$3.191,8455,8932,985Aug 31, 2022, 05:47 PM
Cruse MichaelChief Operating OfficerAug 30, 2022 Buy$3.169753,08131,758Aug 31, 2022, 05:47 PM
Jindal Vineet R.Chief Financial OfficerAug 25, 2021 Buy$7.445,00037,1765,000Aug 26, 2021, 05:54 PM
FLESHER GREGORY J.President and CEOAug 25, 2021 Buy$8.008,00064,0008,000Aug 26, 2021, 05:52 PM
Cruse MichaelSenior VP-Corporate OperationsAug 25, 2021 Buy$7.452,50018,6162,500Aug 26, 2021, 05:51 PM
Muralidhar BaliDirectorJul 14, 2021 Buy$8.50111,736949,7562,073,957Jul 15, 2021, 05:34 PM
Johnson Wendy S.Chief Development OfficerJul 14, 2021 Sale$8.50111,736949,7560Jul 15, 2021, 05:33 PM
Johnson Wendy S.Chief Development OfficerJul 08, 2021 Option Exercise$1.97111,736220,120111,736Jul 09, 2021, 06:52 PM
Muralidhar BaliDirectorJun 22, 2021 Buy$8.7214,615127,4871,941,511Jun 23, 2021, 08:33 AM
Muralidhar BaliDirectorJun 21, 2021 Buy$9.0332,659294,9271,926,896Jun 23, 2021, 08:33 AM
Muralidhar BaliDirectorJun 08, 2021 Buy$9.5016,605157,7091,894,237Jun 10, 2021, 09:00 AM
Muralidhar BaliDirectorJun 04, 2021 Buy$9.422572,4221,877,632Jun 07, 2021, 08:53 AM
Muralidhar BaliDirectorJun 03, 2021 Buy$9.2512,100111,9431,877,375Jun 07, 2021, 08:53 AM
Muralidhar BaliDirectorMay 28, 2021 Buy$9.50141331,865,275Jun 02, 2021, 10:37 AM
Muralidhar BaliDirectorMay 27, 2021 Buy$9.261,12010,3691,865,261May 28, 2021, 04:10 PM
Muralidhar BaliDirectorMay 26, 2021 Buy$9.385,91555,4951,864,141May 28, 2021, 04:10 PM
New Enterprise Associates 15, L.P.10% OwnerApr 13, 2021 Buy$15.00666,6669,999,9904,785,494Apr 15, 2021, 06:16 PM
O'Donnell NiallDirectorApr 13, 2021 Buy$15.00200,0003,000,0002,063,713Apr 15, 2021, 04:16 PM
Muralidhar BaliDirectorApr 13, 2021 Buy$15.00200,0003,000,0001,858,226Apr 15, 2021, 04:15 PM
Novo Holdings A/S10% OwnerApr 13, 2021 Buy$15.00666,6669,999,9903,430,377Apr 14, 2021, 04:44 PM
RiverVest Venture Fund III, L.P.10% OwnerApr 09, 2021 Buy$15.00200,0003,000,0002,409,220Apr 13, 2021, 05:54 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Hall AshleyChief Development Officer08/28/202328,125
Hall AshleyChief Development Officer08/28/202398,058
Novo Holdings A/S10% Owner06/23/2023709,740
O'Donnell NiallDirector05/08/20231,000,000
Cruse MichaelChief Operating Officer09/01/202225,447
GREY MICHAEL GExecutive Chairman08/31/202298,500
Cruse MichaelChief Operating Officer08/29/20223,694
Cruse MichaelChief Operating Officer08/29/2022269
Cruse MichaelChief Operating Officer08/31/202210,307
Cruse MichaelChief Operating Officer08/30/20225,893
Cruse MichaelChief Operating Officer08/30/20223,081
Jindal Vineet R.Chief Financial Officer08/25/202137,176
FLESHER GREGORY J.President and CEO08/25/202164,000
Cruse MichaelSenior VP-Corporate Operations08/25/202118,616
Muralidhar BaliDirector07/14/2021949,756
Johnson Wendy S.Chief Development Officer07/14/2021949,756
Johnson Wendy S.Chief Development Officer07/08/2021220,120
Muralidhar BaliDirector06/22/2021127,487
Muralidhar BaliDirector06/21/2021294,927
Muralidhar BaliDirector06/08/2021157,709
Muralidhar BaliDirector06/04/20212,422
Muralidhar BaliDirector06/03/2021111,943
Muralidhar BaliDirector05/28/2021133
Muralidhar BaliDirector05/27/202110,369
Muralidhar BaliDirector05/26/202155,495
New Enterprise Associates 15, L.P.10% Owner04/13/20219,999,990
O'Donnell NiallDirector04/13/20213,000,000
Muralidhar BaliDirector04/13/20213,000,000
Novo Holdings A/S10% Owner04/13/20219,999,990
RiverVest Venture Fund III, L.P.10% Owner04/09/20213,000,000
Load More Insider Transactions
FUNDS WITH A POSITION IN RENEO PHARMACEUTICALS INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
BLACKROCK INC.618,8200.00014%35.43%Other
GEODE CAPITAL MANAGEMENT, LLC330,6290.0003%12.28%Other
ADAGE CAPITAL PARTNERS GP, L.L.C.65,0000.00112%NewOther
RENAISSANCE TECHNOLOGIES LLC36,0000.00047%-41.09%Other
CHANGE IN SHARES OUTSTANDING FOR RENEO PHARMACEUTICALS INC
STOCK BUYBACKS FOR RENEO PHARMACEUTICALS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
09/30/2023
06/30/2023
11.89%
1Q
09/30/2023
12/31/2022
37.62%
3Q
09/30/2023
09/30/2022
38.01%
4Q
09/30/2023
06/30/2022
38.20%
5Q
09/30/2023
03/31/2022
38.23%
6Q
09/30/2023
09/30/2021
38.58%
8Q
Load More

Period of Report: 09/30/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
06/30/2023
11.89%
1Q
12/31/2022
37.62%
3Q
09/30/2022
38.01%
4Q
06/30/2022
38.20%
5Q
03/31/2022
38.23%
6Q
09/30/2021
38.58%
8Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR RENEO PHARMACEUTICALS INC
LOADING...